MedTrace Logo

Sunitinib Treatment on Tissue Sodium Accumulation (TSS2)

NCT04368546 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 6

Last updated 2021-01-27

No results posted yet for this study

Summary

Here, it is investigated how sunitinib, a tyrosine kinase-inhibitor targeting vascular endothelial growth factor receptors, might influence sodium homeostasis in the skin and if this is related to a well-described treatment side-effect of sunitinib, hypertension.

Conditions

  • Renal Cell Cancer Metastatic
  • Hypertension
  • Sodium Imbalance

Interventions

DRUG

Sunitinib

Sponsors & Collaborators

  • German Heart Institute

    collaborator OTHER

  • Charite University, Berlin, Germany

    lead OTHER

Principal Investigators

  • Dominik Müller, PhD · Group leader at the Max Delbruck Center for Molecular Medicine

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-11-01
Primary Completion
2019-02-01
Completion
2020-03-01

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04368546 on ClinicalTrials.gov